RCUS SEC Filings, Earnings & Splits

Arcus Biosciences filed a routine CEO certification (Exhibit 31.1) under Sarbanes-Oxley Section 302 as part of its quarterly Form 10-Q, affirming the accuracy of financial statements and effectiveness of disclosure controls.

Arcus Biosciences reported third-quarter 2026 financial results and provided a pipeline update, highlighting positive clinical data for casdatifan across multiple lines of kidney cancer therapy, upcoming Phase 3 trial initiations, and a strengthened cash position of $694 million plus $288 million in gross proceeds from an October equity financing.

Arcus Biosciences entered into an underwriting agreement to sell 14,285,715 shares of common stock, with an option for underwriters to purchase up to 2,142,857 additional shares, in a public offering managed by Jefferies, Leerink Partners, and TD Securities.

Arcus Biosciences, Inc. is offering 14,285,715 shares of common stock at $17.50 per share, raising approximately $250 million in gross proceeds. The offering includes a 30-day option for underwriters to purchase up to an additional 2,142,857 shares.

Arcus Biosciences, Inc. filed a preliminary prospectus supplement (424B5) for an underwritten public offering of common stock, with an option for underwriters to purchase additional shares within 30 days. The offering size, price, and proceeds are not yet specified in this preliminary filing.

Arcus Biosciences announced preliminary estimated cash, cash equivalents, and marketable securities of approximately $694.0 million as of September 30, 2026, based on unaudited internal estimates. The company noted these figures are subject to completion of financial closing procedures and have not been reviewed by its independent auditor.

Arcus Biosciences filed a Form 8-K cover page with no substantive event disclosure beyond standard registrant identification and cover-page XBRL data.